Abstract
摘要
相似文献
1
Tolcapone for Parkinson's disease.托卡朋用于治疗帕金森病。
Med Lett Drugs Ther. 1998 Jun 5;40(1028):60-1.
2
Catechol-O-methyltransferase inhibitors: new options for Parkinson's disease.
S D J Med. 1999 Aug;52(8):295-7.
3
Catechol-O-methyltransferase inhibitors in Parkinson's disease.
Lancet. 1998 Jun 27;351(9120):1965-6. doi: 10.1016/s0140-6736(05)78659-1.
4
Vitiligo associated with tolcapone and levodopa in a patient with Parkinson's disease.
Ann Pharmacother. 1999 Nov;33(11):1228-9. doi: 10.1345/aph.19090.
5
[COMT inhibition with tolcapone].[托卡朋抑制儿茶酚-O-甲基转移酶]
Nervenarzt. 1996 Jul;67(7 Suppl Comt-hemmu):1-8.
6
COMT inhibitors: management of Parkinson's disease.
Mov Disord. 2002;17 Suppl 4:S45-51. doi: 10.1002/mds.5560.
7
Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone.使用托卡朋治疗的帕金森病患者中左旋多巴的群体药代动力学
Clin Pharmacol Ther. 2000 Jun;67(6):610-20. doi: 10.1067/mcp.2000.106795.
8
COMT inhibition and safety.儿茶酚-O-甲基转移酶抑制作用与安全性。
Funct Neurol. 2001;16(4 Suppl):135-40.
9
[COMT inhibitors].[儿茶酚-O-甲基转移酶抑制剂]
Med Monatsschr Pharm. 1999 May;22(5):138-41.
10
Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.在老年人中使用多次托卡朋剂量优化左旋多巴的药代动力学。
Clin Pharmacol Ther. 1997 Sep;62(3):300-10. doi: 10.1016/S0009-9236(97)90033-3.
引用本文的文献
1
Comorbid medical illness in psychiatric patients.精神科患者的共病性躯体疾病。
Curr Psychiatry Rep. 2000 Jun;2(3):256-63. doi: 10.1007/s11920-996-0019-x.
Zotero 插件